Abstract 656: Discovery of MAbs against difficult GPCRs, ion channels, and transporters using the MPS Discovery Engine®

Integral membrane proteins are important drug targets and monoclonal antibodies (MAbs) directed against them are highly sought for therapeutic purposes. However, the complex structure of membrane protein targets makes the discovery of these MAbs especially challenging. To address this need, we have developed the MPS Discovery Engine® to enable the isolation, characterization, and engineering of monoclonal antibodies for challenging membrane protein targets, including GPCRs, ion channels, and transporters. MPS harnesses the strength of Integral's 10+ years of expertise in membrane protein expression and analysis, as well as proprietary technologies including Lipoparticles for high concentration membrane protein presentation and Shotgun Mutagenesis for comprehensive epitope mapping and MAb optimization. Integral Molecular currently has a pipeline of several dozen MAbs against complex membrane proteins that are involved in a variety of diseases, including cancer, inflammation, pain, and infectious diseases. There are currently no FDA-approved MAbs that target GPCRs, ion channels, or transporters, and MPS provides a pathway to these new and previously intractable targets. Citation Format: Sharon H. Willis, Kimberly Mattia, Riley Payne, Moniquetta Hall, Manu Mabila, Christine Rettew, Joseph Couto, Rohan Keshwara, Cheryl Paes, Benjamin J. Doranz, Joseph Rucker. Discovery of MAbs against difficult GPCRs, ion channels, and transporters using the MPS Discovery Engine®. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 656. doi:10.1158/1538-7445.AM2015-656